MCID: VGN017
MIFTS: 63

Vaginal Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Vaginal Cancer

MalaCards integrated aliases for Vaginal Cancer:

Name: Vaginal Cancer 11 19 41 14 75 33
Malignant Neoplasm of Vagina 11 31
Vaginal Neoplasms 43 71
Primary Malignant Neoplasm of Vagina 33
Vaginal Malignant Epithelial Tumor 58
Malignant Vaginal Neoplasm 71
Malignant Tumour of Vagina 33
Malignant Tumor of Vagina 11
Malignant Vaginal Tumor 11
Carcinoma of Vagina 33
Vaginal Wall Cancer 33
Neoplasm of Vagina 11
Vagina Wall Cancer 33
Vaginal Carcinoma 58
Vaginal Neoplasia 71
Vaginal Neoplasm 16
Vagina Carcinoma 71
Cancer of Vagina 33
Vagina Neoplasm 11
Vaginal Tumor 11

Characteristics:


Age Of Onset:

Vaginal Carcinoma: Adult,Elderly 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:119
ICD9CM 34 184.0
MeSH 43 D014625
NCIt 49 C3437 C7410
SNOMED-CT 68 126921000 188210000
ICD10 31 C52
ICD10 via Orphanet 32 C52
UMLS via Orphanet 72 C0262659
Orphanet 58 ORPHA180247
UMLS 71 C0042237 C0042258 C0262659 more

Summaries for Vaginal Cancer

MedlinePlus: 41 Vaginal cancer is a rare type of cancer. It is more common in women 60 and older. You are also more likely to get it if you have had a human papillomavirus (HPV) infection or if your mother took diethylstilbestrol (DES) when she was pregnant. Doctors prescribed DES in the 1950's to prevent miscarriages. You are also at higher risk if you have had abnormal cells in the vagina, cervix, or uterus. It often doesn't have early symptoms. However, see your doctor if you notice: Bleeding that is not your period A vaginal lump Pelvic pain A Pap test can find abnormal cells that may be cancer. Vaginal cancer can often be cured in its early stages. Treatment might include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

MalaCards based summary: Vaginal Cancer, also known as malignant neoplasm of vagina, is related to vaginal endometrial stromal tumor and vagina sarcoma, and has symptoms including pelvic pain and vaginal pruritus. An important gene associated with Vaginal Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Disease and ERK Signaling. The drugs Octreotide and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include vagina, cervix and uterus, and related phenotypes are homeostasis/metabolism and nervous system

Orphanet: 58 A group of rare vaginal tumors comprising HPV-associated and HPV-independent squamous cell carcinoma, glandular tumors (including HPV-associated adenocarcinoma, endometrioid carcinoma, clear cell carcinoma, gastric type and intestinal type mucinous carcinoma, and mesonephric adenocarcinoma), adenocarcinoma of Skene gland origin, adenosquamous carcinoma, and adenoid basal carcinoma. Depending on the type of tumor and disease stage, patients may present with symptoms related to a vaginal mass, vaginal bleeding and/or discharge, postcoital bleeding, urinary symptoms, pelvic pain, and a foreign body sensation within the vagina.

Disease Ontology: 11 A female reproductive system cancer that is located in the vagina.

Wikipedia: 75 Vaginal cancer is an extraordinarily rare form of cancer that develops in the tissue of the vagina.... more...

Related Diseases for Vaginal Cancer

Diseases related to Vaginal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 626)
# Related Disease Score Top Affiliating Genes
1 vaginal endometrial stromal tumor 31.7 MME CALD1
2 vagina sarcoma 31.4 PGR MME ESR1 CALD1
3 vaginal disease 31.4 MAPK8IP1 ESR1 CD8A CD4
4 vaginal carcinosarcoma 31.0 TP53 MME KRT7 HRAS
5 neuroendocrine carcinoma 30.1 PTEN PGR KRT7 ESR1
6 suppressor of tumorigenicity 3 30.1 UBE3A TP53 CDKN2A
7 vulval paget's disease 30.0 KRT7 CDKN2A
8 mesenchymal cell neoplasm 30.0 TP53 MME CALD1
9 endometriosis 29.9 TP53 PTEN PGR ESR1
10 mammary paget's disease 29.9 PGR KRT7 ESR1
11 clear cell adenocarcinoma 29.7 TP53 MME KRT7
12 vaginal discharge 29.7 PGR MAPK8IP1 KRT7 ESR1 CD4
13 leiomyosarcoma 29.7 TP53 PGR ESR1 CDKN2A CD274 BRCA1
14 human papillomavirus infectious disease 29.6 TP53 PTEN HRAS GP5 EGFR CDKN2A
15 adult t-cell leukemia/lymphoma 29.6 TP53 CD8A CD4
16 small cell carcinoma 29.6 TP53 PTEN KRT7 EGFR
17 endometrial hyperplasia 29.5 TP53 PTEN PGR ESR1 CDKN2A
18 cervix uteri carcinoma in situ 29.5 TP53 MAPK8IP1 INSM1 GP5 CDKN2A CD4
19 severe cutaneous adverse reaction 29.5 CD8A CD4 CD274
20 cervical squamous cell carcinoma 29.5 TP53 PTEN EGFR CDKN2A
21 rectal benign neoplasm 29.4 TP53 KRT7 HRAS EGFR
22 cervical cancer 29.4 UBE3A TP53 PTEN HRAS CDKN2A
23 squamous cell carcinoma 29.3 TP53 PTEN KRT7 HRAS EGFR CDKN2A
24 adenosquamous carcinoma 29.2 PGR MAPK8IP1 KRT7 INSM1 HRAS EGFR
25 anogenital venereal wart 29.2 UBE3A TP53 GP5 CDKN2A CD8A CD4
26 myoma 29.1 TP53 PGR MME ESR1 EGFR CALD1
27 papilloma 29.0 UBE3A TP53 PTEN KRT7 EGFR CDKN2A
28 keratinizing squamous cell carcinoma 29.0 TP53 KRT7 HRAS EGFR CDKN2A
29 vulva cancer 29.0 TP53 PTEN KRT7 HRAS GP5 EGFR
30 breast ductal carcinoma 29.0 TP53 PTEN PGR KRT7 ESR1 EGFR
31 vulva squamous cell carcinoma 29.0 TP53 HRAS GP5 EGFR CDKN2A CD274
32 squamous cell carcinoma, head and neck 28.8 TP53 PTEN HRAS EGFR CDKN2A
33 adenocarcinoma 28.8 TP53 PTEN KRT7 HRAS EGFR CDKN2A
34 adenocarcinoma in situ 28.5 TP53 MAPK8IP1 KRT7 INSM1 HRAS GP5
35 vulvar disease 28.3 TP53 PTEN KRT7 HRAS GP5 EGFR
36 endometrial cancer 28.0 TP53 PTEN PGR MME KRT7 HRAS
37 anus cancer 27.9 UBE3A TP53 KRT7 HRAS GP5 EGFR
38 connective tissue disease 27.8 TP53 PTEN HRAS ESR1 EGFR CDKN2A
39 rhabdomyosarcoma 27.7 TP53 PTEN MME KRT7 HRAS ESR1
40 leukemia, acute myeloid 27.1 TP53 PTEN MME HRAS ESR1 EGFR
41 cervix carcinoma 26.8 TP53 PTEN PGR MAPK8IP1 KRT7 INSM1
42 vaginal glandular tumor 11.0
43 vaginal squamous tumor 11.0
44 vaginal yolk sac tumor 11.0
45 diethylstilbestrol syndrome 11.0
46 early invasive cervical adenocarcinoma 10.4 INSM1 CDKN2A
47 adenosquamous breast carcinoma 10.4 TP53 PGR
48 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.4 TP53 CDKN2A
49 nipple carcinoma 10.4 PGR ESR1
50 breast mucinous cystadenocarcinoma 10.4 PGR ESR1

Comorbidity relations with Vaginal Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Cervical Cancer
Deficiency Anemia Vulva Cancer

Graphical network of the top 20 diseases related to Vaginal Cancer:



Diseases related to Vaginal Cancer

Symptoms & Phenotypes for Vaginal Cancer

UMLS symptoms related to Vaginal Cancer:


pelvic pain; vaginal pruritus

MGI Mouse Phenotypes related to Vaginal Cancer:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 BRCA1 CD274 CD4 CDKN2A EGFR ESR1
2 nervous system MP:0003631 10.37 BRCA1 CD4 CD8A CDKN2A EGFR ESR1
3 cellular MP:0005384 10.31 BRCA1 CD274 CD4 CD8A CDKN2A EGFR
4 endocrine/exocrine gland MP:0005379 10.27 BRCA1 CD4 CD8A CDKN2A EGFR ESR1
5 no phenotypic analysis MP:0003012 10.24 CD274 CD4 CDKN2A EGFR ESR1 HRAS
6 neoplasm MP:0002006 10.21 BRCA1 CDKN2A EGFR ESR1 HRAS LRIG2
7 normal MP:0002873 10.2 BRCA1 CD8A EGFR ESR1 GP5 HRAS
8 behavior/neurological MP:0005386 10.18 BRCA1 CD274 CDKN2A ESR1 HRAS LRIG2
9 renal/urinary system MP:0005367 10.16 BRCA1 CALD1 CD8A EGFR ESR1 HRAS
10 muscle MP:0005369 10.15 BRCA1 CALD1 CDKN2A EGFR ESR1 HRAS
11 immune system MP:0005387 10.13 BRCA1 CD274 CD4 CD8A CDKN2A EGFR
12 digestive/alimentary MP:0005381 10.09 BRCA1 CD4 CDKN2A EGFR ESR1 HRAS
13 respiratory system MP:0005388 9.86 BRCA1 CDKN2A EGFR ESR1 HRAS INSM1
14 mortality/aging MP:0010768 9.86 BRCA1 CALD1 CD274 CD4 CD8A CDKN2A
15 skeleton MP:0005390 9.85 BRCA1 CD274 CDKN2A EGFR ESR1 HRAS
16 integument MP:0010771 9.5 BRCA1 CD274 CD4 CD8A CDKN2A EGFR

Drugs & Therapeutics for Vaginal Cancer

Drugs for Vaginal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
2
Ondansetron Approved, Withdrawn Phase 3 99614-02-5 4595
3
Granisetron Approved, Investigational Phase 3 109889-09-0 3510 5284566
4
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
5 Immunologic Factors Phase 3
6 Vaccines Phase 3
7 Antineoplastic Agents, Hormonal Phase 3
8 Gastrointestinal Agents Phase 3
9 Dermatologic Agents Phase 3
10 Antipsychotic Agents Phase 3
11 Anti-Anxiety Agents Phase 3
12 Antiemetics Phase 3
13 Emetics Phase 3
14
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
15
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
16
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
17
Fondaparinux Approved, Investigational Phase 2 114870-03-0, 104993-28-4 5282448 636380
18
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
19
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
20
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
21
Bupropion Approved Phase 2 31677-93-7, 34841-39-9, 34911-55-2 444
22
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
23
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
24
Avelumab Approved, Investigational Phase 2 1537032-82-8
25
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
26
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
27
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
28
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
29
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
30
Entinostat Investigational Phase 1, Phase 2 209783-80-2 4261
31 Albumin-Bound Paclitaxel Phase 2
32 Antimetabolites Phase 2
33 Alkylating Agents Phase 1, Phase 2
34 Antirheumatic Agents Phase 1, Phase 2
35 Antineoplastic Agents, Alkylating Phase 1, Phase 2
36 Immunosuppressive Agents Phase 1, Phase 2
37 Fibrinolytic Agents Phase 2
38 Factor Xa Inhibitors Phase 2
39 PENTA Phase 2
40 HIV Protease Inhibitors Phase 2
41 Anticoagulants Phase 2
42 Serine Proteinase Inhibitors Phase 2
43 Antithrombins Phase 2
44 Antithrombin III Phase 2
45
protease inhibitors Phase 2
46 Anti-Bacterial Agents Phase 2
47 Calcineurin Inhibitors Phase 2
48 Cyclosporins Phase 2
49 Antifungal Agents Phase 2
50 Antitubercular Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
2 A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women Completed NCT00543543 Phase 3
3 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
4 A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND) Completed NCT00003267 Phase 3
5 A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) Completed NCT00943722 Phase 3
6 An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) Completed NCT03158220 Phase 3
7 A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Completed NCT04425291 Phase 3
8 A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged16-26 Years Completed NCT05372016 Phase 3
9 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
10 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Completed NCT01536392 Phase 3 Granisetron;Ondansetron
11 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
12 A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™ Completed NCT01047345 Phase 3
13 Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial Recruiting NCT04895020 Phase 3
14 A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Recruiting NCT04422366 Phase 3
15 Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial Recruiting NCT05027776 Phase 3
16 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Active, not recruiting NCT02466971 Phase 3 Cisplatin;Triapine
17 Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study Unknown status NCT00905658 Phase 2
18 A Phase 2 Study of Triapine® (NSC #663249) and Cisplatin in Combination With Pelvic Radiation for Treatment of Stage IB2-IVa Cervical Cancer or Stage II-IV Vaginal Cancer Completed NCT00941070 Phase 2 triapine;cisplatin
19 A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies Completed NCT01079832 Phase 2
20 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
21 A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women Completed NCT00551187 Phase 2
22 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2
23 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
24 A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
25 Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial Completed NCT00381888 Phase 2 fondaparinux sodium
26 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
27 EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA Completed NCT00002562 Phase 2 paclitaxel
28 Effectiveness of an Individualized Symptom Education Program (ISEP) on the Symptom Distress of Women Receiving Radiation for Gynecological Cancer. Completed NCT00275353 Phase 2
29 A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO) Completed NCT01399658 Phase 2 3'-Deoxy-3'-18f-Fluorothymidine
30 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
31 A Pilot Study of Conformal Intensity Modulated Radiation Therapy (IMRT) for Gynaecological Cancer Patients Not Suitable for Intracavitary Brachytherapy Boost (GY03.2) Completed NCT00188578 Phase 1, Phase 2
32 Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer Completed NCT03180294 Phase 2 Bupropion 150 mg XL;Placebo
33 A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Recruiting NCT04708470 Phase 1, Phase 2 Bintrafusp Alfa;NHS-IL12;Entinostat
34 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
35 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Active, not recruiting NCT03439085 Phase 2
36 A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers Not yet recruiting NCT05639972 Phase 1, Phase 2 Conditioning, E7 TCR-T cells, and aldesleukin
37 A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer Terminated NCT00106262 Phase 2 Velcade (bortezomib);Irinotecan
38 A Phase II Study of Sacral Nerve Stimulation for Low Anterior Resection Syndrome or Fecal Incontinence in Patients Following a Low Anterior Resection or Proctectomy With Coloanal Anastomosis or in Patients After Pelvic Chemoradiation (RESTORE) Terminated NCT04066894 Phase 2
39 A Phase I/II Feasibility/Efficacy Study of HIFU in Otherwise Untreatable Pelvic Rectal Cancer Withdrawn NCT01097239 Phase 1, Phase 2
40 A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn NCT03220009 Phase 2
41 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
42 Phase I Study of Intravenous Triapine® (IND #68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies. Completed NCT00335998 Phase 1 triapine;cisplatin
43 A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years Completed NCT03676101 Phase 1
44 A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL™ Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX™ (IMX) Completed NCT00851643 Phase 1
45 A Phase I Study of Weekly Oral Topotecan in Gynecologic Malignancies Completed NCT00842452 Phase 1 topotecan hydrochloride
46 Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy Completed NCT02058550 Phase 1
47 Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies Completed NCT00002949 Phase 1 paclitaxel;vinorelbine tartrate
48 A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
49 Phase I Study of Metronomic Daily Dosing of Docetaxel in Women With Progressive or Recurrent Gynecologic Cancer Completed NCT00287885 Phase 1 docetaxel
50 MRI Guided Brachytherapy for HPV-Associated Cervical and Vaginal Malignancies Recruiting NCT03634267 Phase 1

Search NIH Clinical Center for Vaginal Cancer

Cochrane evidence based reviews: vaginal neoplasms

Genetic Tests for Vaginal Cancer

Anatomical Context for Vaginal Cancer

Organs/tissues related to Vaginal Cancer:

FMA: Vagina
MalaCards : Cervix, Uterus, Breast, T Cells, Bone, Colon, Lymph Node

Publications for Vaginal Cancer

Articles related to Vaginal Cancer:

(show top 50) (show all 1031)
# Title Authors PMID Year
1
Innovations in the Management of Vaginal Cancer. 62 41
35621640 2022
2
Primary vaginal endodermal sinus tumor in infants and children: experience from a tertiary center. 41
36207682 2022
3
Trends in the Incidence of Vulvar and Vaginal Cancers With Different Histology by Race, Age, and Region in the United States (2001-2018). 41
36105176 2022
4
Intensity-modulated brachytherapy for vaginal cancer. 62
36069978 2022
5
Pelvic organ prolapse and vaginal cancer: A systematic literature review. 62
35167139 2022
6
Uterine Leiomyosarcoma Masquerading as a Malignant Perivascular Epithelioid Cell Tumor: A Diagnostic Challenge. 62
36310451 2022
7
Postmenopausal Vaginal and Cervical Cancer Risk Related to In Utero Diethylstilbestrol Exposure. 62
36222810 2022
8
Outcomes of 3D MRI based HDR brachytherapy with hybrid multichannel vaginal cylinder applicator and freehand needles for treatment of vaginal disease. 62
36266203 2022
9
Small cell neuroendocrine carcinoma of vagina: Report of a unique case with literature review. 62
36274474 2022
10
Neuroendocrine carcinoma of vagina with prolonged survival. 62
36316052 2022
11
Pap smear outcomes in elderly women living with HIV and HIV-negative matched controls. 62
35980835 2022
12
A modern-day experience with Brunschwig's operation: Outcomes associated with pelvic exenteration. 62
36064678 2022
13
Cellular angiofibroma of the vagina: A case report and literature review. 62
36107545 2022
14
Factors that affect survival in vaginal cancer: a seer analysis. 62
35543117 2022
15
Our clinical experience in pelvic magnetic resonance imaging with vaginal contrast. 62
35997217 2022
16
Vaginal yolk sac tumor resected by a novel laparo/endoscope-assisted posterior sagittal approach: a case report. 62
36036317 2022
17
Protein Expression Profiling and Virtual Drug Screening as an Approach for Individualized Therapy of Small Cell Vaginal Carcinoma. 62
35732326 2022
18
Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014. 62
35633031 2022
19
Implementation of Image-Guided Brachytherapy for Pediatric Vaginal Cancers: Feasibility and Early Clinical Results. 62
35805018 2022
20
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. 62
35248212 2022
21
First clinical experience with a novel, mobile cone-beam CT system for treatment quality assurance in brachytherapy. 62
35278094 2022
22
Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis. 62
35551568 2022
23
A lipidic mesophase with tunable release properties for the local delivery of macromolecules: the apoferritin nanocage, a case study. 62
35470843 2022
24
Second primary malignancies in cervical cancer and endometrial cancer survivors: a population-based analysis. 62
35507749 2022
25
[Analysis on cancer incidence and mortality attributed to human papillomavirus infection in China, 2016]. 62
35589576 2022
26
[Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors]. 62
35658326 2022
27
Primary Vaginal Adenocarcinoma of Intestinal-Type: A Case Report of a Rare Tumor With Review of Histology, Differential Diagnosis, and Literature. 62
35755502 2022
28
Vaginal leiomyoma mimicking a Cystocele (report case). 62
35364392 2022
29
Primary poorly differentiated carcinoma of the vagina with focal neuroendocrine differentiation: a tumour with aggressive behaviour. 62
35396236 2022
30
Malignant mesenchymal vaginal tumor mimicking pedunculated submucous myoma: A case report. 62
35318185 2022
31
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. 62
35428697 2022
32
Vaginal cancer: Why should we care? Anatomy, staging and in-depth imaging-based review of vaginal malignancies focusing on MRI and PET/CT. 62
35151129 2022
33
18F-FDG PET/CT in Patients with Vulvar and Vaginal Cancer: A Preliminary Study of 20 Cases. 62
34818510 2022
34
Assessing the Effectiveness of Web-Based Modules on Human Papillomavirus Among Dental and Dental Hygiene Students. 62
35296971 2022
35
Updates in the treatment of vaginal cancer. 62
35256422 2022
36
BEBIG 60Co HDR brachytherapy source dosimetric parameters validation using GATE Geant4-based simulation code. 62
35368537 2022
37
Patient perspectives and experiences of the rapid implementation of digital consultations during COVID-19 - a qualitative study among women with gynecological cancer. 62
34796401 2022
38
Combined modality including novel sensitizers in gynecological cancers. 62
35256428 2022
39
Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. 62
34974906 2022
40
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013. 62
35026864 2022
41
Benign mixed Müllerian (duct) vaginal tumor in a 12-y-old goat. 62
35000511 2022
42
Bevacizumab increases late toxicity in re-irradiation with image-guided high-dose-rate brachytherapy for gynecologic malignancies. 62
35233235 2022
43
Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications? 62
35159024 2022
44
Surgical management of vaginal cancer and concomitant complete uterovaginal prolapse. 62
34735589 2022
45
Role of radiotherapy in the treatment of primary vaginal cancer: Recommendations of the French society for radiation oncology. 62
34955415 2022
46
Optimization of catheter's implementation in the mold, in the case of vaginal HDR brachytherapy treatment. 62
36299389 2022
47
Development and validation of models for predicting the overall survival and cancer-specific survival of patients with primary vaginal cancer: A population-based retrospective cohort study. 62
36106318 2022
48
Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980-2018). 62
35115839 2022
49
Evaluation of dyskerin expression and the Cajal body protein WRAP53β as potential prognostic markers for patients with primary vaginal carcinoma. 62
34868367 2022
50
Comparison of the clinical performance of a hybrid Alba 4D and the AMC-4 locoregional hyperthermia systems. 62
36355063 2022

Variations for Vaginal Cancer

Cosmic variations for Vaginal Cancer:

8 (show top 50) (show all 1122)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM139294266 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 21
2 COSM103491068 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 21
3 COSM99883612 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.816-2A>G p.? 17:42329778-42329778 21
4 COSM88453086 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 21
5 COSM140296740 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 21
6 COSM97074901 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3409G>A p.E1137K 20:42106824-42106824 21
7 COSM142601992 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.2256G>A p.E753K 20:42106824-42106824 21
8 COSM144161135 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.2206G>A p.E736K 20:42106824-42106824 21
9 COSM96630253 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3382G>A p.E1128K 20:42106824-42106824 21
10 COSM96848041 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3349G>A p.E1117K 20:42106824-42106824 21
11 COSM97172725 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3322G>A p.E1108K 20:42106824-42106824 21
12 COSM96960471 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3418G>A p.E1140K 20:42106824-42106824 21
13 COSM93285904 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3379G>A p.E1127K 20:42106824-42106824 21
14 COSM96733209 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3352G>A p.E1118K 20:42106824-42106824 21
15 COSM92613846 NSD1 vagina,NS,carcinoma,squamous cell carcinoma c.4910G>T p.G1637V 5:177280659-177280659 21
16 COSM109089776 NSD1 vagina,NS,carcinoma,squamous cell carcinoma c.5717G>T p.G1906V 5:177280659-177280659 21
17 COSM92689842 NSD1 vagina,NS,carcinoma,squamous cell carcinoma c.4910G>T p.G1637V 5:177280659-177280659 21
18 COSM86305871 NFKBIA vagina,NS,carcinoma,squamous cell carcinoma c.127G>C p.E43Q 14:35404518-35404518 21
19 COSM133974130 NFKBIA vagina,NS,carcinoma,squamous cell carcinoma c.127G>C p.E43Q 14:35404518-35404518 21
20 COSM102100255 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.331G>T p.E111* 23:20130530-20130530 21
21 COSM102100262 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.17-2734G>C p.? 23:20138575-20138575 21
22 COSM102126713 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.415G>T p.E139* 23:20130530-20130530 21
23 COSM102126718 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.64G>C p.E22Q 23:20138575-20138575 21
24 COSM88614470 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 21
25 COSM101446479 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 21
26 COSM94832378 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 21
27 COSM101464008 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 21
28 COSM101457530 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 21
29 COSM101451548 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 21
30 COSM101460995 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 21
31 COSM92091529 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 21
32 COSM97571573 ATRX vagina,NS,carcinoma,squamous cell carcinoma c.4498G>A p.E1500K 23:77652173-77652173 21
33 COSM100346016 ATRX vagina,NS,carcinoma,squamous cell carcinoma c.4384G>A p.E1462K 23:77652173-77652173 21
34 COSM123189243 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.270G>A p.L90= 8:116848969-116848969 8
35 COSM127848324 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.127G>A p.E43K 8:116848969-116848969 8
36 COSM123189233 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.249G>A p.L83= 8:116848948-116848948 8
37 COSM127848316 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.106G>A p.E36K 8:116848948-116848948 8
38 COSM101184918 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4630C>G p.L1544V 16:2086857-2086857 8
39 COSM90408532 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4906C>G p.L1636V 16:2086857-2086857 8
40 COSM149806850 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4843C>G p.L1615V 16:2086857-2086857 8
41 COSM87033167 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4975C>G p.L1659V 16:2086857-2086857 8
42 COSM151515645 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4900C>G p.L1634V 16:2086857-2086857 8
43 COSM150318236 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4774C>G p.L1592V 16:2086857-2086857 8
44 COSM102623419 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4774C>G p.L1592V 16:2086857-2086857 8
45 COSM151373080 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4969C>G p.L1657V 16:2086857-2086857 8
46 COSM150359241 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4771C>G p.L1591V 16:2086857-2086857 8
47 COSM151750121 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4846C>G p.L1616V 16:2086857-2086857 8
48 COSM110108009 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4666C>G p.L1556V 16:2086857-2086857 8
49 COSM148986154 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4777C>G p.L1593V 16:2086857-2086857 8
50 COSM136621744 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4807C>G p.L1603V 16:2086857-2086857 8

Expression for Vaginal Cancer

Search GEO for disease gene expression data for Vaginal Cancer.

Pathways for Vaginal Cancer

Pathways related to Vaginal Cancer according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 BRCA1 CD4 CDKN2A EGFR ESR1 GP5
2
Show member pathways
13.66 TP53 PTEN OGN MAPK8IP1 HRAS ESR1
3
Show member pathways
13.59 UBE3A TP53 OGN HRAS ESR1 EGFR
4
Show member pathways
13.34 TP53 PTEN OGN MAPK8IP1 HRAS EGFR
5
Show member pathways
12.81 TP53 PTEN HRAS EGFR CDKN2A CD4
6 12.76 PGR HRAS ESR1 EGFR CD274
7
Show member pathways
12.59 TP53 PTEN HRAS EGFR CDKN2A
8 12.41 TP53 PTEN HRAS EGFR CDKN2A CD274
9
Show member pathways
12.38 TP53 PTEN HRAS ESR1
10 12.33 TP53 MAPK8IP1 HRAS EGFR
11
Show member pathways
12.29 PGR ESR1 CDKN2A BRCA1
12
Show member pathways
11.95 PGR HRAS ESR1 EGFR
13 11.95 TP53 PTEN ESR1 EGFR BRCA1
14 11.84 MME GP5 CD8A CD4
15 11.78 TP53 PTEN HRAS CDKN2A
16 11.68 MME CD8A CD4
17 11.67 TP53 PTEN ESR1
18 11.63 UBE3A ESR1 EGFR
19
Show member pathways
11.61 TP53 PTEN HRAS CDKN2A CD8A CD4
20 11.6 BRCA1 ESR1 PGR
21
Show member pathways
11.6 TP53 PTEN PGR HRAS ESR1 EGFR
22 11.57 UBE3A CDKN2A BRCA1
23 11.57 CDKN2A ESR1 PTEN TP53
24 11.55 UBE3A TP53 CDKN2A
25
Show member pathways
11.55 UBE3A PTEN HRAS
26 11.5 TP53 PTEN HRAS BRCA1
27 11.42 TP53 PTEN HRAS EGFR CDKN2A
28 11.31 TP53 PTEN ESR1
29 11.29 TP53 PTEN BRCA1
30 11.22 TP53 HRAS EGFR CDKN2A
31 11.19 PGR ESR1 EGFR

GO Terms for Vaginal Cancer

Biological processes related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast proliferation GO:0048144 9.63 TP53 HRAS ESR1
2 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.56 TP53 ESR1
3 replicative senescence GO:0090399 9.43 TP53 MME CDKN2A
4 regulation of cell cycle GO:0051726 9.36 TP53 PTEN INSM1 HRAS CDKN2A BRCA1

Molecular functions related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.47 TP53 PTEN PGR ESR1 EGFR CD4

Sources for Vaginal Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....